These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19841030)

  • 1. Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.
    Adriaenssens N; Goossens H; Coenen S;
    J Antimicrob Chemother; 2009 Dec; 64(6):1347. PubMed ID: 19841030
    [No Abstract]   [Full Text] [Related]  

  • 2. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.
    Nathwani D
    J Antimicrob Chemother; 2009 Sep; 64(3):447-53. PubMed ID: 19584105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme.
    Seaton RA; Macconnachie AA
    Int J Antimicrob Agents; 2008 May; 31(5):492-7. PubMed ID: 18313274
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.
    Shrestha NK; Mason P; Gordon SM; Neuner E; Nutter B; O'Rourke C; Rehm SJ
    J Antimicrob Chemother; 2014 May; 69(5):1407-15. PubMed ID: 24398341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient parenteral antimicrobial therapy: Recent developments and future prospects.
    Török ME; Chapman AL; Lessing MP; Sanderson F; Seaton RA
    Curr Opin Investig Drugs; 2010 Aug; 11(8):929-39. PubMed ID: 20721835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience.
    Seaton RA; Gonzalez-Ramallo VJ; Prisco V; Marcano-Lozada M; Gonzalez-Ruiz A; Gallegos B; Menichetti F; Loeffler J; Bouylout K; Chaves RL
    Int J Antimicrob Agents; 2013 May; 41(5):468-72. PubMed ID: 23473943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
    Tice AD
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii83-6. PubMed ID: 15150187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daptomycin in outpatient antimicrobial parenteral therapy].
    Cervera C; Mestres CA
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():59-63. PubMed ID: 22541978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe.
    Coenen S; Muller A; Adriaenssens N; Vankerckhoven V; Hendrickx E; Goossens H;
    J Antimicrob Chemother; 2009 Jul; 64(1):200-5. PubMed ID: 19383728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
    Schrank GM; Wright SB; Branch-Elliman W; LaSalvia MT
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):947-954. PubMed ID: 29893658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience with high-dosage daptomycin for prosthetic infections.
    De Rosa FG; Mollaretti O; Cometto C; Pagani N; Montrucchio C; Di Perri G
    Clin Infect Dis; 2009 Dec; 49(11):1772-3. PubMed ID: 19891570
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
    Sader HS; Watters AA; Fritsche TR; Jones RN
    J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.